Olanzapine Found Effective for Managing TKI-Related Side Effects

Olanzapine ameliorated nausea, vomiting, weight loss, insomnia and anorexia related to tyrosine kinase inhibitors ...

MAY 12, 2025

Stopping TKIs Can Be Done Safely While Slashing Cost of Therapy

Discontinuing tyrosine kinase inhibitors is safe for patients with chronic myeloid leukemia who have mounted a deep ...

MAY 5, 2023

Double Checkpoint Inhibitors Plus TKI Improves Control of RCC

In patients with advanced renal cell carcinoma, the addition of the tyrosine kinase inhibitor cabozantinib ...

OCTOBER 3, 2022

New Indication Granted for Bosutinib to Treat Newly Diagnosed Ph+ CML

Bosulif is now indicated for adults with newly diagnosed chronic phase, Philadelphia chromosome–positive ...

DECEMBER 30, 2017

Strategies for Stopping TKIs in CML Growing Clearer

San Diego—In patients with CML, longer treatment duration is associated with an increase in the odds ratio ...

MARCH 14, 2017

PD Expression May Predict TKI-Related Outcomes of mRCC

Patients mRCC that expresses programmed death cells experience poorer overall and progression-free survival with ...

FEBRUARY 15, 2017

Most TKI Recipients Require Dose Optimization To Achieve Adequate Drug Levels

Over 50% of patients treated with a tyrosine kinase inhibitor do not initially have adequate serum drug levels and ...

OCTOBER 14, 2016